We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Neurobiology of Opioid Dependence: 2 - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000193
Recruitment Status : Withdrawn
First Posted : September 21, 1999
Last Update Posted : August 7, 2015
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Gamma hydroxybutyric Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Neurobiology of Opioid Dependence: 2
Study Start Date : January 1993
Primary Completion Date : January 1998
Study Completion Date : January 1998

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Behavioral, subjective, measures of naloxone-preci
  2. Phsyiological, neuroendocrine measures of naloxone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000193

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000193     History of Changes
Other Study ID Numbers: NIDA-00191-2
K20DA000191 ( U.S. NIH Grant/Contract )
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: August 7, 2015
Last Verified: August 2015

Keywords provided by Yale University:
Opioid disorders

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents